Benzinga··Vandana SinghBoston Scientific Plunges 9% on Trial Win Paradox as Growth Concerns Overshadow Data
$BSX shares dropped 9.02% to 52-week lows despite positive WATCHMAN FLX and EKOS trial results, signaling investor caution amid broader growth concerns.
BSXclinical trial resultsmedical devices